Pfizer

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, March 11, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Cancer, Court, Biotechnology, Person, The Company, BioNTech, Omicron, Food, Complaint, Risk, COVID-19, BNTX, Infection, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points: 
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Court, Person, BioNTech, Telephone, Loss, District court, Risk, COVID-19, BNTX, P.C

Investors have until March 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Thursday, March 7, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Thursday, March 7, 2024
GPM, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Court, Suite, Forecasting, The Company, BioNTech, News, Risk, COVID-19, BNTX, COVID, Defendant, Pharmaceutical industry

On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.

Key Points: 
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Thursday, March 7, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Retrieved on: 
Thursday, March 7, 2024
Hydrogen, DARPA, Acquisition, Pfizer, Hospital, Rocky, Restaurant, Hydrogen peroxide, Food safety, Disinfectant, Annual report, Health, Growth, Cell, Monroe Dunaway Anderson, Horsepower, Meat, University, School, Supervisor, Decontamination, MD Anderson Cancer Center, Police, Medication, Trust, Paint, Corporation, Partnership

FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.

Key Points: 
  • FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.
  • SteraMist iHP technology is becoming the standard decontamination technology in the life sciences sector and academic institutions with a broad spectrum of clients equipped with mobile systems, custom integrations, and service contracts.
  • In a notable development, Rising Pharmaceuticals has entered into an ongoing annual contract with TOMI’s SteraMist iHP Corporate Service following the acquisition of a building previously serviced by the team.
  • SteraMist iHP Corporate Service managed to decontaminate our entire facility quickly without causing harm to the infrastructure or our sensitive equipment.

BioNTech Announces Planned Retirement of Sean Marett

Retrieved on: 
Thursday, March 7, 2024
Pfizer, Supervisory board, BioNTech, Entrepreneurship, IPO, Commercial, COVID-19, BNTX, Companion, Science, Research, Film industry

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.

Key Points: 
  • Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.
  • Sean Marett’s responsibilities as Chief Business Officer are beeing gradually transferred to James Ryan, Ph.D., Chief Legal Officer, who will also take on the role of Chief Business Officer of BioNTech at the end of the transition phase and upon Sean Marett’s retirement.
  • Sean Marett joined BioNTech as a member of the Management Board in 2012.
  • Sean Marett was a key member of the team that ensured liquidity of over $1 billion in funding as a private company.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 6, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Retrieved on: 
Tuesday, March 5, 2024
Pfizer, PSMA, Database, Safety, LAVA, Pharmaceutical industry

UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment of $7 Million to LAVA.

Key Points: 
  • UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment of $7 Million to LAVA.
  • LAVA granted Seagen (acquired by Pfizer in December 2023) a worldwide, exclusive license to PF-08046052 in September 2022.
  • “We are very pleased with the initiation of clinical development by Pfizer of PF-08046052, formerly SGN-EGFRd2/LAVA-1223.
  • Achievement of this milestone is another important step in realizing the potential of LAVA’s Gammabody® platform.

BioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline

Retrieved on: 
Monday, March 4, 2024
Pfizer–BioNTech COVID-19 vaccine, The Company, Pfizer, COVID-19, BNTX, BioNTech, Risk, Pharmaceutical industry

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) investors that a lawsuit was filed on behalf of investors that purchased B. Riley securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) investors that a lawsuit was filed on behalf of investors that purchased B. Riley securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.